PRINCETON, N.J. — Sandoz has entered into a long-term agreement with Civica Rx to manufacture and supply critical injectable generic medicines, to help reduce supply shortages and ensure acute care settings can deliver optimal patient care. Under the five-year agreement, Sandoz will supply six injectable medicines widely used at Civica’s 1,200 U.S. member hospitals, to
HOLZKIRCHEN, Germany – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States District Court of New Jersey ruled against Sandoz in patent litigation concerning the Sandoz biosimilar, Erelzi (etanercept-szzs) for reference medicine Enbrel (etanercept). The company will appeal the ruling to the US Court of Appeals for the
STAMFORD, Conn. – Americares, in partnership with the Healthcare Distribution Alliance (HDA), has presented its annual Power of Partnership Award to Novartis and its Sandoz division, in recognition of their outstanding commitment to increasing access to health care around the world. Americares senior vice president of global programs Dr. E. Anne Peterson presented the award
BASEL – Novartis announced this week that Richard Francis will be stepping down as chief executive officer of Sandoz, a Novartis division, and as a member of the executive committee of Novartis on March 31. Francesco Balestrieri, currently region head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will report to Vas Narasimhan, CEO, Novartis.
HOLZKIRCHEN, Germany — Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that it has entered into an agreement to commercialize biosimilar versions of insulins used in patients with type 1 and type 2 diabetes. These medicines are currently in early and clinical stages of development for the European Union (E.U.),
HOLZKIRCHEN— Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced today the commercial launch of reSET for patients with Substance Use Disorder (SUD). reSET, the first and only FDA-authorized prescription digital therapeutic, is immediately available. Study results from a multicenter, randomized clinical trial showed that reSET, when used with outpatient therapy and contingency management, significantly improved abstinence
HOLZKIRCHEN, Germany — Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn’s
HOLZKIRCHEN, Germany — Following Food and Drug Administration final approval, Sandoz has launched of Glatopa 40 mg/ml (glatiramer acetate injection), a multiple sclerosis medication. The Novartis division said Tuesday that Glatopa 40 mg/ml, manufactured in the United States, was developed under a collaboration pact with Momenta Pharmaceuticals Inc. The product is a fully substitutable generic version of
PRINCETON, N.J. — Sandoz Inc. has launched olopatadine hydrochloride ophthalmic solution 0.2%, an antihistamine for itchy eyes, in the United States. Sandoz said the product is an authorized generic version of Pataday eye drops from Alcon. Both Sandoz and Alcon are subsidiaries of Novartis. A mast cell stabilizer, olopatadine hydrochloride ophthalmic solution 0.2% is indicated
WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly
MAPLE GROVE, Minn. — Upsher-Smith Laboratories Inc. has entered an agreement to sell its AmLactin skin care brand to Sandoz Inc. Financial terms of the deal weren’t disclosed. Upsher-Smith said the move is part of its strategy of focusing on generic drugs and novel therapies. AmLactin is formulated to gently exfoliate and relieve dryness associated
PRINCETON, N.J. — Sandoz Inc. has introduced bimatoprost ophthalmic solution 0.03%, an eyelash treatment, in the U.S. market. The Novartis subsidiary said its bimatoprost ophthalmic product is a generic version of Latisse from Allergan. A prescription medicine, bimatoprost ophthalmic solution 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length,
WASHINGTON — Though the vast majority of specialty physicians know what biosimilars are, their knowledge about these emerging medications falls short, according to a survey by the Biosimilars Forum. Of 1,201 U.S. physicians polled, 76.8% had heard the term biosimilars within the previous month, the Biosimilars Forum said Tuesday. Yet respondents exhibited five key gaps
PRINCETON, N.J. — Sandoz has launched rosuvastatin calcium tablets, a cholesterol-lowering medication, in the United States. The Novartis division said Thursday that its rosuvastatin calcium product, a generic version of Crestor from AstraZeneca Pharmaceuticals, will be marketed in dosages of 5 mg, 10 mg, 20 mg and 40 mg. U.S. sales for Crestor totaled approximately
